Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Future Virol. 2011 Feb;6(2):157–177. doi: 10.2217/fvl.10.89

Table 1.

Steady-state pharmacokinetics of atazanavir in HIV-infected patients in a fed state.

Dosage Cmax in ng/ml (%) Cmin† in ng/ml (%) Half-life in hours (%) AUC in ng-h/ml (%)
Atazanavir 400 mg once daily 2298 (71) 120 (109) 6.5 (2.6) 14,874 (91)
Atazanavir 300 mg + ritonavir 100 mg once daily 4422 (58) 636 (97) 8.6 (2.3) 46,073 (66)

All values not in parentheses are the geometric mean. The percentage values are the coefficient of variation.

†

Recommended therapeutic target for optimal virologic suppression, Cmin >150 ng/ml [114].

AUC: Area under the plasma concentration–time curve; Cmax: Maximum (peak) plasma concentration; Cmin: Minimum (trough) plasma concentration.